Evaluating the effect of Roxadustat on ventricular repolarization in patients undergoing peritoneal dialysis

Abstract Background Roxadustat is a novel oral medication used to treat anemia in CKD patients. Several studies have shown that Roxadustat can alleviate anemia in CKD patients by increasing hemoglobin levels and regulating iron metabolism. We aimed to evaluate the effect of Roxadustat on ventricular...

Full description

Bibliographic Details
Main Authors: Yangyang Zhang, Liang Zhang, Pengcheng Ge, Ruyi Xu, Zhen Ye
Format: Article
Language:English
Published: BMC 2023-10-01
Series:European Journal of Medical Research
Subjects:
Online Access:https://doi.org/10.1186/s40001-023-01368-0
_version_ 1827723847540932608
author Yangyang Zhang
Liang Zhang
Pengcheng Ge
Ruyi Xu
Zhen Ye
author_facet Yangyang Zhang
Liang Zhang
Pengcheng Ge
Ruyi Xu
Zhen Ye
author_sort Yangyang Zhang
collection DOAJ
description Abstract Background Roxadustat is a novel oral medication used to treat anemia in CKD patients. Several studies have shown that Roxadustat can alleviate anemia in CKD patients by increasing hemoglobin levels and regulating iron metabolism. We aimed to evaluate the effect of Roxadustat on ventricular repolarization in PD patients. This study may provide a new integrated approach to the assessment and treatment of CKD. Methods The present prospective cohort study enrolled 65 CKD patients who were treated with Roxadustat and 31 CKD patients who received conventional therapy between January 2021 and June 2022. All patients were examined for ECG in the absence of clinical symptoms and compared the ECG indicators. Demographic and clinical data of all patients were collected. All data used SPSS 18.0 for statistical analyses. Results The T peak-to-end (Tpe) of PD patients in the Roxadustat group was remarkably slower than that of patients in the conventional group. Additionally, the Tpe/QT ratio in the conventional group was significantly elevated than that in the Roxadustat group. The results of logistic regression analysis showed that Tpe (95%CI 1.191 ~ 2.141, P = 0.002) and Roxadustat treatment (95%CI 1.357 ~ 42.121, P = 0.021) were the risk factors of PD patients with high Tp-e/QT ratio. Conclusion In summary, we found that Roxadustat could improve ventricular repolarization in peritoneal dialysis patients, which indicated a potential cardiovascular protective effect of Roxadustat. This study might provide a new integrated approach to the assessment and treatment of CKD.
first_indexed 2024-03-10T22:06:31Z
format Article
id doaj.art-998c01e780044e23a511607754c626bd
institution Directory Open Access Journal
issn 2047-783X
language English
last_indexed 2024-03-10T22:06:31Z
publishDate 2023-10-01
publisher BMC
record_format Article
series European Journal of Medical Research
spelling doaj.art-998c01e780044e23a511607754c626bd2023-11-19T12:47:03ZengBMCEuropean Journal of Medical Research2047-783X2023-10-012811610.1186/s40001-023-01368-0Evaluating the effect of Roxadustat on ventricular repolarization in patients undergoing peritoneal dialysisYangyang Zhang0Liang Zhang1Pengcheng Ge2Ruyi Xu3Zhen Ye4Department of Cardiology, Suqian First HospitalDepartment of Nephrology, Suqian First HospitalDepartment of Cardiology, Suqian First HospitalDepartment of Nephrology, Suqian First HospitalDepartment of Pharmacy, Suqian First HospitalAbstract Background Roxadustat is a novel oral medication used to treat anemia in CKD patients. Several studies have shown that Roxadustat can alleviate anemia in CKD patients by increasing hemoglobin levels and regulating iron metabolism. We aimed to evaluate the effect of Roxadustat on ventricular repolarization in PD patients. This study may provide a new integrated approach to the assessment and treatment of CKD. Methods The present prospective cohort study enrolled 65 CKD patients who were treated with Roxadustat and 31 CKD patients who received conventional therapy between January 2021 and June 2022. All patients were examined for ECG in the absence of clinical symptoms and compared the ECG indicators. Demographic and clinical data of all patients were collected. All data used SPSS 18.0 for statistical analyses. Results The T peak-to-end (Tpe) of PD patients in the Roxadustat group was remarkably slower than that of patients in the conventional group. Additionally, the Tpe/QT ratio in the conventional group was significantly elevated than that in the Roxadustat group. The results of logistic regression analysis showed that Tpe (95%CI 1.191 ~ 2.141, P = 0.002) and Roxadustat treatment (95%CI 1.357 ~ 42.121, P = 0.021) were the risk factors of PD patients with high Tp-e/QT ratio. Conclusion In summary, we found that Roxadustat could improve ventricular repolarization in peritoneal dialysis patients, which indicated a potential cardiovascular protective effect of Roxadustat. This study might provide a new integrated approach to the assessment and treatment of CKD.https://doi.org/10.1186/s40001-023-01368-0RoxadustatVentricular repolarizationPeritoneal dialysisElectrocardiogramCoronary atherosclerosis
spellingShingle Yangyang Zhang
Liang Zhang
Pengcheng Ge
Ruyi Xu
Zhen Ye
Evaluating the effect of Roxadustat on ventricular repolarization in patients undergoing peritoneal dialysis
European Journal of Medical Research
Roxadustat
Ventricular repolarization
Peritoneal dialysis
Electrocardiogram
Coronary atherosclerosis
title Evaluating the effect of Roxadustat on ventricular repolarization in patients undergoing peritoneal dialysis
title_full Evaluating the effect of Roxadustat on ventricular repolarization in patients undergoing peritoneal dialysis
title_fullStr Evaluating the effect of Roxadustat on ventricular repolarization in patients undergoing peritoneal dialysis
title_full_unstemmed Evaluating the effect of Roxadustat on ventricular repolarization in patients undergoing peritoneal dialysis
title_short Evaluating the effect of Roxadustat on ventricular repolarization in patients undergoing peritoneal dialysis
title_sort evaluating the effect of roxadustat on ventricular repolarization in patients undergoing peritoneal dialysis
topic Roxadustat
Ventricular repolarization
Peritoneal dialysis
Electrocardiogram
Coronary atherosclerosis
url https://doi.org/10.1186/s40001-023-01368-0
work_keys_str_mv AT yangyangzhang evaluatingtheeffectofroxadustatonventricularrepolarizationinpatientsundergoingperitonealdialysis
AT liangzhang evaluatingtheeffectofroxadustatonventricularrepolarizationinpatientsundergoingperitonealdialysis
AT pengchengge evaluatingtheeffectofroxadustatonventricularrepolarizationinpatientsundergoingperitonealdialysis
AT ruyixu evaluatingtheeffectofroxadustatonventricularrepolarizationinpatientsundergoingperitonealdialysis
AT zhenye evaluatingtheeffectofroxadustatonventricularrepolarizationinpatientsundergoingperitonealdialysis